CA2465386C - Use of glycosaminoglycans and zinc derivatives for insect bites, stings and the like - Google Patents
Use of glycosaminoglycans and zinc derivatives for insect bites, stings and the like Download PDFInfo
- Publication number
- CA2465386C CA2465386C CA002465386A CA2465386A CA2465386C CA 2465386 C CA2465386 C CA 2465386C CA 002465386 A CA002465386 A CA 002465386A CA 2465386 A CA2465386 A CA 2465386A CA 2465386 C CA2465386 C CA 2465386C
- Authority
- CA
- Canada
- Prior art keywords
- zinc
- zinc oxide
- stings
- heparin
- insect bites
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000006877 Insect Bites and Stings Diseases 0.000 title claims abstract description 48
- 150000003751 zinc Chemical class 0.000 title abstract description 25
- 229920002683 Glycosaminoglycan Polymers 0.000 title abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims abstract description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims abstract description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims abstract description 4
- 235000011187 glycerol Nutrition 0.000 claims abstract description 4
- 229950008882 polysorbate Drugs 0.000 claims abstract description 4
- 229920000136 polysorbate Polymers 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 47
- 229920000669 heparin Polymers 0.000 claims description 31
- 239000011787 zinc oxide Substances 0.000 claims description 25
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims description 10
- 241000282414 Homo sapiens Species 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000029663 wound healing Effects 0.000 abstract description 26
- 208000003251 Pruritus Diseases 0.000 abstract description 25
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract description 24
- 230000000699 topical effect Effects 0.000 abstract description 13
- -1 methylparaban Polymers 0.000 abstract description 5
- 239000000969 carrier Substances 0.000 abstract description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 abstract description 4
- 239000002628 heparin derivative Substances 0.000 abstract description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 abstract description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 abstract description 2
- 229960003415 propylparaben Drugs 0.000 abstract description 2
- 229960002897 heparin Drugs 0.000 description 21
- 235000014692 zinc oxide Nutrition 0.000 description 18
- 208000027418 Wounds and injury Diseases 0.000 description 15
- 238000011282 treatment Methods 0.000 description 12
- 206010052428 Wound Diseases 0.000 description 11
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 9
- 229920002674 hyaluronan Polymers 0.000 description 9
- 229960003160 hyaluronic acid Drugs 0.000 description 9
- 239000011701 zinc Substances 0.000 description 9
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 8
- 239000003102 growth factor Substances 0.000 description 8
- 230000007803 itching Effects 0.000 description 8
- 229910052725 zinc Inorganic materials 0.000 description 8
- 230000036541 health Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000037314 wound repair Effects 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000030961 allergic reaction Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940126864 fibroblast growth factor Drugs 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 208000003014 Bites and Stings Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 206010067152 Oral herpes Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960001008 heparin sodium Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000000651 myofibroblast Anatomy 0.000 description 2
- 230000014508 negative regulation of coagulation Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 2
- 206010002388 Angina unstable Diseases 0.000 description 1
- 241001425390 Aphis fabae Species 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- AEMOLEFTQBMNLQ-HNFCZKTMSA-N L-idopyranuronic acid Chemical group OC1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-HNFCZKTMSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229940105847 calamine Drugs 0.000 description 1
- 239000008338 calamine lotion Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- QNDQILQPPKQROV-UHFFFAOYSA-N dizinc Chemical compound [Zn]=[Zn] QNDQILQPPKQROV-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 1
- 229960001971 ebastine Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 229910052864 hemimorphite Inorganic materials 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000029774 keratinocyte migration Effects 0.000 description 1
- AEMOLEFTQBMNLQ-CLQWQSTFSA-N l-iduronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O AEMOLEFTQBMNLQ-CLQWQSTFSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008215 regulation of wound healing Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
- 235000009529 zinc sulphate Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A composition of glycosaminoglycans and zinc derivatives and its application to accelerate wound healing and to reduce pruritus resulted from insect bites, stings and the like are disclosed. Effective amount of zinc derivatives in the range of 1-20 mg/g is admixed with effective amount of glycosaminoglycan, such as heparin derivative, in the range of 100-300 USP units/g in a gel for topical application on the affected area. Suitable non-medicinal carriers selected from the group consisting of carboxymethylcellulose, glycerin, methylparaban, polysorbate, propylparaben and water may be added to the composition gel.
Description
USE OF GLYCOSAMINOGLYCANS AND ZINC DERIVATIVES
FOR INSECT BITES, STINGS AND THE LIKE
FIELD OF THE INVENTION
The invention relates to a composition of glycosaminoglycans and zinc derivatives and its use to effectively accelerate wound healing and reduce pruritus resulted from insect bites, stings and the like.
BACKGROUND OF THE INVENTION
List ofPrior Art Literatures Agren. MS (1990) Studies on zinc in wound healing. Acta Derm Venereol Suppl (Stockh) 154:1-36.
Agren MS (1999) Zinc in wound repair. Arch Dermatol 135:1273-1274.
Agren MS, Krusell M, Franzen L (1991) Release and absorption of zinc from zinc oxide and zinc sulfate in open wounds. Acta Denn Venereol 71:330-333.
Agren MS, Steenfos HH, Tarnow P, Jansson JO (2001) Zinc oxide augments engogenous expression of insulin-like growth factor-I (IC~F-I) and activates matrix metalloproteinases (MMPs) in wounds. EWMA Journal l :l--3.
Bourin MC, Lindahl U (1993} Glycosaminoglycans and the regulation of blood coagulation. Biochem J 289 ( Pt 2):313-330.
Brissett AE, Hom DB (2003) The effects of tissue sealants, platelet gels, and growth factors on wound healing. Curr Opin Otolaryngol Head Neclc Surg 11:245-250.
Chen WY, Abatangelo G (1999) Functions of hyaluronan in wound repair. Wound Repair Regen 7:79-89.
Derry JE, McLean WM, Freeman JB (1983) A study of the percutaneous absorption from topically applied zinc oxide ointment. J Parenter Enteral Nutr 7:131-135.
Godfrey HR, Godfrey NJ, Godfrey JC, Riley D (2001) A .randomized clinical trial on the treatment of oral herpes with topical zinc oxide/glycine. Altern Ther Health Med 7:49-56.
Harding KG, Morris HL, Patel GK (2002} Science, medicine and the future:
healing chronic wounds. Bmj 324:160-163.
Karppinen A, Kautiainen H, Petman L, Burri P, Reunala T (2002) Comparison of cetirizine, ebastine and loratadine in the treatment of immediate mosquito-bite allergy.
Allergy 57:534-537.
Kratz G, Arnander C, Swedenborg J, Back M, Falk C, Gouda I, Larm O (1997) Heparin-chitosan complexes stimulate wound healing in human skin. Scand J
Plast Reconstr Surg Hand Surg 31:119-123.
Majerus PW, Tollefsen DM (2001) Anticoagulant, thrombolytic, and anti-platelet drugs. In: Goodman & Gilman°s The pharmacological basis of therapeutics, 10 Edition (Hardman JG, Limbird LE, Goodman Gilman A, eds), pp 1519-1538. New York: McGraw-Hill.
Moreland LW (2003} Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. Arthritis Res Ther 5:54-67.
Noble PW (2002) Hyaluronan and its catabolic products in. tissue injury and repair.
Matrix Biol 21:25-29.
FOR INSECT BITES, STINGS AND THE LIKE
FIELD OF THE INVENTION
The invention relates to a composition of glycosaminoglycans and zinc derivatives and its use to effectively accelerate wound healing and reduce pruritus resulted from insect bites, stings and the like.
BACKGROUND OF THE INVENTION
List ofPrior Art Literatures Agren. MS (1990) Studies on zinc in wound healing. Acta Derm Venereol Suppl (Stockh) 154:1-36.
Agren MS (1999) Zinc in wound repair. Arch Dermatol 135:1273-1274.
Agren MS, Krusell M, Franzen L (1991) Release and absorption of zinc from zinc oxide and zinc sulfate in open wounds. Acta Denn Venereol 71:330-333.
Agren MS, Steenfos HH, Tarnow P, Jansson JO (2001) Zinc oxide augments engogenous expression of insulin-like growth factor-I (IC~F-I) and activates matrix metalloproteinases (MMPs) in wounds. EWMA Journal l :l--3.
Bourin MC, Lindahl U (1993} Glycosaminoglycans and the regulation of blood coagulation. Biochem J 289 ( Pt 2):313-330.
Brissett AE, Hom DB (2003) The effects of tissue sealants, platelet gels, and growth factors on wound healing. Curr Opin Otolaryngol Head Neclc Surg 11:245-250.
Chen WY, Abatangelo G (1999) Functions of hyaluronan in wound repair. Wound Repair Regen 7:79-89.
Derry JE, McLean WM, Freeman JB (1983) A study of the percutaneous absorption from topically applied zinc oxide ointment. J Parenter Enteral Nutr 7:131-135.
Godfrey HR, Godfrey NJ, Godfrey JC, Riley D (2001) A .randomized clinical trial on the treatment of oral herpes with topical zinc oxide/glycine. Altern Ther Health Med 7:49-56.
Harding KG, Morris HL, Patel GK (2002} Science, medicine and the future:
healing chronic wounds. Bmj 324:160-163.
Karppinen A, Kautiainen H, Petman L, Burri P, Reunala T (2002) Comparison of cetirizine, ebastine and loratadine in the treatment of immediate mosquito-bite allergy.
Allergy 57:534-537.
Kratz G, Arnander C, Swedenborg J, Back M, Falk C, Gouda I, Larm O (1997) Heparin-chitosan complexes stimulate wound healing in human skin. Scand J
Plast Reconstr Surg Hand Surg 31:119-123.
Majerus PW, Tollefsen DM (2001) Anticoagulant, thrombolytic, and anti-platelet drugs. In: Goodman & Gilman°s The pharmacological basis of therapeutics, 10 Edition (Hardman JG, Limbird LE, Goodman Gilman A, eds), pp 1519-1538. New York: McGraw-Hill.
Moreland LW (2003} Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. Arthritis Res Ther 5:54-67.
Noble PW (2002) Hyaluronan and its catabolic products in. tissue injury and repair.
Matrix Biol 21:25-29.
Prasad AS (1991) Discovery of human zinc deficiency and studies in an experimental human model. Am J Clin Nutr 53:403-412.
Rittenhouse T (1996) The management of lower-extremity ulcers with zinc-saline wet dressings versus normal saline wet dressings. Adv Ther 13:88-94.
SCCNFP: The Scientific Committee on Cosmetic Products and Non-Food Products intended for Consumers (2003) Evaluation and opinion on: Zinc oxide. Colipa n° S
76.
Saliba MJ, Jr. (1997) The effects and uses of heparin in the care of burns that improves treatment and enhances the quality of life. Acta Chir Plast 39:13-16.
Saliba MJ, Jr. (2001) Heparin in the treatment of burns: a review. Burns 27:349-358.
Saliba MJ, Jr., Dempsey WC, Kruggel JL (1973) Large burns in humans. Treatment with heparin. Jama 225:261-269.
Santos MC, Souza AP, Gerlach RF, Tabchoury CM, Lime SR (2001) Inhibition of human gelatinases (matrix metalloproteinase-2 and matrix metalloproteinase-9) activity by zinc oxide: a possible mechanism to enhance wound healing. Br J
Dermatol 145:854-855.
Tarnow P, Agren M, Steenfos H, Jansson JO (1994) Topical zinc oxide treatment increases endogenous gene expression of insulin-like growth factor-1 in granulation tissue from porcine wounds. Scand J Plast Reconstr Surg Hand Surg 28:255-259.
Vazquez JR, Short B, Findlow AH, Nixon BP, Boulton AJ, Armstrong DG (2003) Outcomes of hyaluronan therapy in diabetic foot wounds. Diabetes Res Clin Pract 59:123-127.
Rittenhouse T (1996) The management of lower-extremity ulcers with zinc-saline wet dressings versus normal saline wet dressings. Adv Ther 13:88-94.
SCCNFP: The Scientific Committee on Cosmetic Products and Non-Food Products intended for Consumers (2003) Evaluation and opinion on: Zinc oxide. Colipa n° S
76.
Saliba MJ, Jr. (1997) The effects and uses of heparin in the care of burns that improves treatment and enhances the quality of life. Acta Chir Plast 39:13-16.
Saliba MJ, Jr. (2001) Heparin in the treatment of burns: a review. Burns 27:349-358.
Saliba MJ, Jr., Dempsey WC, Kruggel JL (1973) Large burns in humans. Treatment with heparin. Jama 225:261-269.
Santos MC, Souza AP, Gerlach RF, Tabchoury CM, Lime SR (2001) Inhibition of human gelatinases (matrix metalloproteinase-2 and matrix metalloproteinase-9) activity by zinc oxide: a possible mechanism to enhance wound healing. Br J
Dermatol 145:854-855.
Tarnow P, Agren M, Steenfos H, Jansson JO (1994) Topical zinc oxide treatment increases endogenous gene expression of insulin-like growth factor-1 in granulation tissue from porcine wounds. Scand J Plast Reconstr Surg Hand Surg 28:255-259.
Vazquez JR, Short B, Findlow AH, Nixon BP, Boulton AJ, Armstrong DG (2003) Outcomes of hyaluronan therapy in diabetic foot wounds. Diabetes Res Clin Pract 59:123-127.
Walsh CT, Sandstead HH, Prasad AS, Newberne PM, Fraker PJ (1994) Zinc: health effects and research priorities for the 1990s. Environ Health Perspect 102 Suppl 2:5-46.
Werner S, Grose R (2003) Regulation of wound healing by growth factors and cytokines. Physiol Rev 83:835-870.
World Health Organization. (1997) WHO model prescribing information : drugs used in skin diseases. Geneva: World Health Organilzation.
Wyatt EL, Sutter SH, Drake LA (2001) Dermatological pharmacology. In: Goodman & Gilman's The pharmacological basis of therapeutics, 10 Edition (Hardman JG, Limbird LE, Goodman Gilman A, eds), pp 1795-1819. New York: McGraw-Hill.
Insect bites, such as caused by mosquitoes, can lead to an allergic reaction and pruritus (itching), which is mediated in part by the production of antisaliva IgE
antibodies and histamine (Karppinen et al., 2002). Antihistamines such as cetirizine and ebastine administered propylatically have been demonstrated to significantly decrease pruritus caused by mosquito bites (Karppinen et al., 2002). Topical application of calamine lotion (which usually contains zinc oxide and calamine) at the site of the insect bite, sting or the like is also indicated for symptomatic relief of mild pruritus (World Health Organization, 1997). Topical application of glucocorticosteroids such as hydrocortisone are used to relieve pruritus and in the treatment of inflammatory skin diseases (Wyatt et al., 2001; World Health Organization, 1997), but are not commonly used for the treatment of insect bites, stings and the like. In short, current methods for treatment of insect bites, stings and the like are directed towards minimizing/controlling the allergic/inflammatory reaction and symptomatic relief of pruritus.
Use of glycosaminoglycans, such as hyaluronic acid, as a single active ingredient to treat ailments, including insect bites is known (see U.S. Patent Nos.
Werner S, Grose R (2003) Regulation of wound healing by growth factors and cytokines. Physiol Rev 83:835-870.
World Health Organization. (1997) WHO model prescribing information : drugs used in skin diseases. Geneva: World Health Organilzation.
Wyatt EL, Sutter SH, Drake LA (2001) Dermatological pharmacology. In: Goodman & Gilman's The pharmacological basis of therapeutics, 10 Edition (Hardman JG, Limbird LE, Goodman Gilman A, eds), pp 1795-1819. New York: McGraw-Hill.
Insect bites, such as caused by mosquitoes, can lead to an allergic reaction and pruritus (itching), which is mediated in part by the production of antisaliva IgE
antibodies and histamine (Karppinen et al., 2002). Antihistamines such as cetirizine and ebastine administered propylatically have been demonstrated to significantly decrease pruritus caused by mosquito bites (Karppinen et al., 2002). Topical application of calamine lotion (which usually contains zinc oxide and calamine) at the site of the insect bite, sting or the like is also indicated for symptomatic relief of mild pruritus (World Health Organization, 1997). Topical application of glucocorticosteroids such as hydrocortisone are used to relieve pruritus and in the treatment of inflammatory skin diseases (Wyatt et al., 2001; World Health Organization, 1997), but are not commonly used for the treatment of insect bites, stings and the like. In short, current methods for treatment of insect bites, stings and the like are directed towards minimizing/controlling the allergic/inflammatory reaction and symptomatic relief of pruritus.
Use of glycosaminoglycans, such as hyaluronic acid, as a single active ingredient to treat ailments, including insect bites is known (see U.S. Patent Nos.
5,650,157, 6,103,704, 6,576,650 and U.S. Patent Application Publication No.
2003/0027833). Likewise, UT.S. Patent Nos. 4,879,282 and 5,037,810 teach the use of heparin for relieving pruritus. These prior art tend to address the most conspicuous aspect of insect bites, namely itching. They do not seem to deal with the wound healing aspect of the ailment. Thus, it is beneficial to have a composition which can be used to promote insect bite wound healing as well as to reduce pruritus.
This invention teaches wound healing of insect bites, stings and the like by topically applying effective amounts of glycosaminoglycans and zinc derivatives mixtures to the injured site for accelerated healing.
SUMMARY OF THE INVENTION
It is an object of the invention to provide for an effective compound for promoting effective healing of insect bites, stings and the like on humans.
According to one aspect of the invention, it provides a composition to promote wound healing and to reduce pruritus resulted from insect bites, comprising a therapeutically effective amount of zinc derivative and glycosaminoglycan admixed with non-medicinal carriers.
It is another object of the invention to provide for a method to promote wound healing and reduce pruritus resulting from insect bites. According to another aspect of the invention, it provides a method for promoting wound healing and reducing pruritus resulted from insect bites, comprising applying topically to the affected area an effective amount of zinc derivative and glycosaminoglycan composition admixed with non-medicinal carriers.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
In order to understand the mechanism of action of the present invention which uses glycosaminoglycans, such as heparin, and zinc derivatives for promoting wound healing and reducing pruritus of insect bites, stings and the like, the pharmacological characteristics of each of these compounds must first be understood.
Cationic Zinc Zinc (Zn) is a naturally occurring trace element generally considered to be a non-toxic metal (Walsh et al., 1994). In its divalent cationic form, Znz+ can be found in virtually every mammalian cell. Zn2+ is critical for the activity of a number of enzymes and proteins and is necessary for DNA synthesis, cell division and gene expression (Agren et al., 2001; Prasad et al., 1991). To maintain human health, Zn2+
must be consumed through dietary intake; indeed, Zn2+ deficiency resulting from either insufficient intake or diseased conditions (e.g. chronic renal failure) can lead to clinical symptoms (Prasad et al., 1991).
Zinc derivatives, primarily zinc oxide, are currently used in skin ointments, baby and skin creams, toothpaste, deodorants and sunscreens (SCCNFP report on Zinc Oxide, 2003). Toxicological studies using topical applications and oral administration of zinc derivatives (zinc oxide or zinc sulphate) in both animal models and humans indicate little or no toxicity (SCCNFP report on Zinc Oxide, 2003).
Furthermore, application of a zinc oxide-containing ointment (2.68g daily dose) to the skin of humans suffering from psoriasis did not significantly elevate plasma levels of Zn2+ (Derry et al., 1983). Based on currently available toxicological and pharmacological studies and extensive topical use of cationic zinc, topical application of zinc derivatives for the treatment of insect bites, stings and the like is expected to be safe and well-tolerated.
Heparin A glycosaminoglycan, heparin is a polymer composed of alternating N-acetyl-glucosamine residues and D-glucoronic acid (reviewed in Bourin and Lindahl, 1993).
The glucosamine residues can be deacetylated and sulfated on the amine residue on C2 or can be O-sulfated at the C3 and C6 position. The D-glucoronic acid residue can epimerize to L-iduronic acid and both glucoronic and iduronic acid residues can be O-sulfated at the C-2 position. Heparin derives its name from its high abundance in liver and can be found in tissues that contain mast cells (reviewed in Majerus and Tollefsen, 2001). Heparin is a potent anticoagulant with a rapid onset of action and is widely used clinically to treat venous thrombosis, pulmonary embolism, unstable angina, myocardial infarction and other vascular conditions requiring anticoagulant activity (reviewed in Majerus and Tollefsen, 2001). It is administered parenterally or by subcutaneous injection, with daily doses ranging from 10,000 to 40,000 USP
units for the majority of clinical applications related to anticoagulant activity (Majerus and Tollefsen, 2001).
Other Glycosaminoglycans Hyaluronic acid (HA), a polymer composed of the repeating disaccharide motif (3-1,4-glucuronic acid-(31,3-N-acetyl glucosamine, is found in most vertebrate tissues (reviewed in Noble, 2002). This hygroscopic polymer in its high molecular weight form is a component in the extracellular matrix surrounding cells and is important for tissue structural integrity (Noble, 2(102). The intra-articular administration of HA is currently employed for the treatment of osteoarthritis (reviewed in Moreland, 2003). Due to its viscoelasticity, HA is used during ophthalmic surgery (reviewed in Chen and Abatangelo, 1999).
Wound Healing Wound healing following tissue injury can be divided into 4 sequential and overlapping processes: hemostasis, inflammation, proliferation and tissue remodelling (reviewed in Brissett and Hom, 2003). Blood clotting during hemostatis leads to the release of growth factors from platelets, hemostatic factors and inflammatory mediators such as cytokines (reviewed in Werner and Grose, 2002; Brissett and Hom, 2003). During the inflammatory phase, neutrophils phagocytose bacteria and cell debris (reviewed in Handing et al., 2002; Werner and Grose, 2002; Brissett and Hom, 2003). Neutrophils are subsequently replaced by macrophages. In the proliferative phase of wound healing, growth factors involved in angiogenesis and epithelialization such as fibroblast growth factor (FGF), vascular endothelial growth factor, transforming growth factor (3 and oc, platelet-derived growth factor, epidermal growth factor, tumor necrosis factor and interferon, are released from macrophages and platelets (reviewed in Handing et al., 2002; Werner and Grose, 2002; Brissett and Hom, 2003). Fibroblasts migrate from the surrounding tissue, proliferate, deposit extracellular matrix proteins (such as collagen, elastin and integrins) and eventually transform into myofibroblasts (reviewed in Handing et al., 2002; Werner and Grose, 2002; Brissett and Hom, 2003). Keratinocytes proliferate at the edge of the injury and migrate across the wound bed. Wound remodelling involves increased collagen a cross-linking and the destruction of excess collagen by collagenase released from myofibroblasts and macrophages (reviewed in Harding et al., 2002; Werner and Grose, 2002; Brissett and Hom, 2003).
Modulation of Wound Healing by Zinc Derivatives Zinc oxide creams are commonly used for the treatment of diaper rash.
Treatment of oral herpes with a zinc oxide/glycine preparation resulted in a shorter duration of cold sores and reduced blistering, soreness, itching, and tingling (Godfrey et al., 2001).
Zinc oxide is a common component of bandages applied to wounds (Agren et al., 2001 ). Studies have demonstrated that zinc oxide promotes epithelialization during wound repair although the mechanism for this process has yet to be elucidated (Agren, 1990; Rittenhouse, 1996; Agren et al., 2001). Topical application of zinc oxide to porcine wounds leads to enhanced release of growth factors (Tarnow et al., 1994; Agren et al., 2001). In addition, zinc oxide modulates the activity of zinc-dependent matrix metalloproteinases (Agren, 1999; Agrer~ et al., 2001; Santos et al., 2001) which could facilitate keratinocyte migration during wound repair. This modulation by zinc oxide of growth factor release and matrix metalloproteinase activity is postulated to be involved in the epithelialization that occurs during wound repair. The effects of zinc oxide on wound healing are presumed to be the result of increased concentrations of zinc at the site of the injury (A,gren et al., 1991). Hence, any zinc derivative that enhances the concentration of zinc at the site of an injury, such as an insect bites, stings and the like, will be beneficial to wound healing.
2003/0027833). Likewise, UT.S. Patent Nos. 4,879,282 and 5,037,810 teach the use of heparin for relieving pruritus. These prior art tend to address the most conspicuous aspect of insect bites, namely itching. They do not seem to deal with the wound healing aspect of the ailment. Thus, it is beneficial to have a composition which can be used to promote insect bite wound healing as well as to reduce pruritus.
This invention teaches wound healing of insect bites, stings and the like by topically applying effective amounts of glycosaminoglycans and zinc derivatives mixtures to the injured site for accelerated healing.
SUMMARY OF THE INVENTION
It is an object of the invention to provide for an effective compound for promoting effective healing of insect bites, stings and the like on humans.
According to one aspect of the invention, it provides a composition to promote wound healing and to reduce pruritus resulted from insect bites, comprising a therapeutically effective amount of zinc derivative and glycosaminoglycan admixed with non-medicinal carriers.
It is another object of the invention to provide for a method to promote wound healing and reduce pruritus resulting from insect bites. According to another aspect of the invention, it provides a method for promoting wound healing and reducing pruritus resulted from insect bites, comprising applying topically to the affected area an effective amount of zinc derivative and glycosaminoglycan composition admixed with non-medicinal carriers.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
In order to understand the mechanism of action of the present invention which uses glycosaminoglycans, such as heparin, and zinc derivatives for promoting wound healing and reducing pruritus of insect bites, stings and the like, the pharmacological characteristics of each of these compounds must first be understood.
Cationic Zinc Zinc (Zn) is a naturally occurring trace element generally considered to be a non-toxic metal (Walsh et al., 1994). In its divalent cationic form, Znz+ can be found in virtually every mammalian cell. Zn2+ is critical for the activity of a number of enzymes and proteins and is necessary for DNA synthesis, cell division and gene expression (Agren et al., 2001; Prasad et al., 1991). To maintain human health, Zn2+
must be consumed through dietary intake; indeed, Zn2+ deficiency resulting from either insufficient intake or diseased conditions (e.g. chronic renal failure) can lead to clinical symptoms (Prasad et al., 1991).
Zinc derivatives, primarily zinc oxide, are currently used in skin ointments, baby and skin creams, toothpaste, deodorants and sunscreens (SCCNFP report on Zinc Oxide, 2003). Toxicological studies using topical applications and oral administration of zinc derivatives (zinc oxide or zinc sulphate) in both animal models and humans indicate little or no toxicity (SCCNFP report on Zinc Oxide, 2003).
Furthermore, application of a zinc oxide-containing ointment (2.68g daily dose) to the skin of humans suffering from psoriasis did not significantly elevate plasma levels of Zn2+ (Derry et al., 1983). Based on currently available toxicological and pharmacological studies and extensive topical use of cationic zinc, topical application of zinc derivatives for the treatment of insect bites, stings and the like is expected to be safe and well-tolerated.
Heparin A glycosaminoglycan, heparin is a polymer composed of alternating N-acetyl-glucosamine residues and D-glucoronic acid (reviewed in Bourin and Lindahl, 1993).
The glucosamine residues can be deacetylated and sulfated on the amine residue on C2 or can be O-sulfated at the C3 and C6 position. The D-glucoronic acid residue can epimerize to L-iduronic acid and both glucoronic and iduronic acid residues can be O-sulfated at the C-2 position. Heparin derives its name from its high abundance in liver and can be found in tissues that contain mast cells (reviewed in Majerus and Tollefsen, 2001). Heparin is a potent anticoagulant with a rapid onset of action and is widely used clinically to treat venous thrombosis, pulmonary embolism, unstable angina, myocardial infarction and other vascular conditions requiring anticoagulant activity (reviewed in Majerus and Tollefsen, 2001). It is administered parenterally or by subcutaneous injection, with daily doses ranging from 10,000 to 40,000 USP
units for the majority of clinical applications related to anticoagulant activity (Majerus and Tollefsen, 2001).
Other Glycosaminoglycans Hyaluronic acid (HA), a polymer composed of the repeating disaccharide motif (3-1,4-glucuronic acid-(31,3-N-acetyl glucosamine, is found in most vertebrate tissues (reviewed in Noble, 2002). This hygroscopic polymer in its high molecular weight form is a component in the extracellular matrix surrounding cells and is important for tissue structural integrity (Noble, 2(102). The intra-articular administration of HA is currently employed for the treatment of osteoarthritis (reviewed in Moreland, 2003). Due to its viscoelasticity, HA is used during ophthalmic surgery (reviewed in Chen and Abatangelo, 1999).
Wound Healing Wound healing following tissue injury can be divided into 4 sequential and overlapping processes: hemostasis, inflammation, proliferation and tissue remodelling (reviewed in Brissett and Hom, 2003). Blood clotting during hemostatis leads to the release of growth factors from platelets, hemostatic factors and inflammatory mediators such as cytokines (reviewed in Werner and Grose, 2002; Brissett and Hom, 2003). During the inflammatory phase, neutrophils phagocytose bacteria and cell debris (reviewed in Handing et al., 2002; Werner and Grose, 2002; Brissett and Hom, 2003). Neutrophils are subsequently replaced by macrophages. In the proliferative phase of wound healing, growth factors involved in angiogenesis and epithelialization such as fibroblast growth factor (FGF), vascular endothelial growth factor, transforming growth factor (3 and oc, platelet-derived growth factor, epidermal growth factor, tumor necrosis factor and interferon, are released from macrophages and platelets (reviewed in Handing et al., 2002; Werner and Grose, 2002; Brissett and Hom, 2003). Fibroblasts migrate from the surrounding tissue, proliferate, deposit extracellular matrix proteins (such as collagen, elastin and integrins) and eventually transform into myofibroblasts (reviewed in Handing et al., 2002; Werner and Grose, 2002; Brissett and Hom, 2003). Keratinocytes proliferate at the edge of the injury and migrate across the wound bed. Wound remodelling involves increased collagen a cross-linking and the destruction of excess collagen by collagenase released from myofibroblasts and macrophages (reviewed in Harding et al., 2002; Werner and Grose, 2002; Brissett and Hom, 2003).
Modulation of Wound Healing by Zinc Derivatives Zinc oxide creams are commonly used for the treatment of diaper rash.
Treatment of oral herpes with a zinc oxide/glycine preparation resulted in a shorter duration of cold sores and reduced blistering, soreness, itching, and tingling (Godfrey et al., 2001).
Zinc oxide is a common component of bandages applied to wounds (Agren et al., 2001 ). Studies have demonstrated that zinc oxide promotes epithelialization during wound repair although the mechanism for this process has yet to be elucidated (Agren, 1990; Rittenhouse, 1996; Agren et al., 2001). Topical application of zinc oxide to porcine wounds leads to enhanced release of growth factors (Tarnow et al., 1994; Agren et al., 2001). In addition, zinc oxide modulates the activity of zinc-dependent matrix metalloproteinases (Agren, 1999; Agrer~ et al., 2001; Santos et al., 2001) which could facilitate keratinocyte migration during wound repair. This modulation by zinc oxide of growth factor release and matrix metalloproteinase activity is postulated to be involved in the epithelialization that occurs during wound repair. The effects of zinc oxide on wound healing are presumed to be the result of increased concentrations of zinc at the site of the injury (A,gren et al., 1991). Hence, any zinc derivative that enhances the concentration of zinc at the site of an injury, such as an insect bites, stings and the like, will be beneficial to wound healing.
Modulation of Wound Healing by Heparin The ability of heparin to assist in the healing of wounds, especially burn wounds (Saliba et al., 1973; reviewed in Saliba 1997, 2001) is documented, although the mechanism is unclear. Many growth factors, such as acidic and basic FGF, implicated in wound healing bind heparin with high affinity (Majerus and Tollefson, 2001 ). Binding to heparin results in stabilization and activation of these growth factors (Kratz et al., 1997) which are implicated in epithelialization during wound healing. The binding of heparin to growth factors may be responsible for enhanced wound healing. Heparin derivatives are thus expected to be effective for the treatment of insect bites, stings and the like.
Modulation of Wound Healing by Other Glycosamynoglycans Topical application of HA to animals has been shown to accelerate skin wound healing (reviewed in Chen and Abatengelo, 1999). HA in wound dressings has been shown to be beneficial for the healing of diabetic foot wounds (Vazquez et al., 2003). The high quantity of HA in fetal when compared to adult tissues is believed to be linked to scarless wound healing observed in fetal tissues (reviewed in Chen and Abatengelo, 1999). The precise mechanism whereby HA assists in wound healing remains to be determined.
While there exist prior art which teaches treatment of insect bites, stings and the like by applying either zinc and/or zinc derivatives or glycosaminoglycans such as heparin alone, there has no reported discovery of combining the medicinal synergies of these two compounds to treat insect bites.
' CA 02465386 2004-04-19 Combination of Zinc Derivatives and Glycosaminoglycayrs Based on the above understanding, the combination of heparin (or other equivalent glycosaminoglycans) and zinc derivatives in a topical application should, in theory, enhance wound repair. The inventor of the present invention discovered and proved that this is, in fact, the case. Both heparin and zinc derivatives enhance epithilialization by different proposed mechanisms and, when mixed, interact in an additive or synergistic fashion to enhance wound repair. Therefore, combined use of a glycosaminoglycan, such as heparin, with a zinc derivative has significant advantages with respect to wound healing after an injury such as insect bites, stings and the like, when compared to the use of either component alone. In addition, zinc derivatives, such as zinc oxide, reduce itching. Unlike other current treatments for treatment of insect bites, stings and the like which are primarily aimed towards minimizing/controlling the allergic/inflammatory reaction and symptomatic relief of pruritus, the present invention is directed towards accelerating wound healing along with a reduction of pruritus. Thus, the use of both a glycosaminoglycan such as heparin with a zinc derivative such as zinc oxide is essential in order to effectively treat insect bites, stings and the like.
Formulation of Heparin and Zinc deYivatives According to the present invention, it has been found that applying zinc derivatives topically in the range of 1-20 mg/g of the gel and heparin derivatives (such as sodium heparin) topically in the range of 100-300 USP units/g of the gel provides effective therapeutic amount for treating insect bites, stings and the like on humans.
Preferably, the optimal dosage used in the treatment is 5 mg/g of zinc derivatives and 160 USP units/g of heparin of the gel.
Based on currently available toxicological data (SCCNFP report on Zinc Oxide, 2003), the stated dosage range for zinc derivatives is safe and well tolerated.
Likewise, the identified dosage range of heparin will not result in significant elevations in plasma heparin levels, hence will not lead to increased bleeding times, and hence will be safe and well-tolerated by the users. These two active ingredients will be applied topically to the skin at the site of the insect bite, sting or the like, in a gel formulation. Suitably, pharmaceutically acceptable carriers may be added to the application gel. Examples of non-medicinal carriers can be selected from the group consisting of carboxymethylcellulose, glycerin, methylparaban, polysorbate, propylparaben and water.
The preferred embodiment of the present invention will be further described by the following examples.
Example 1 The female black fly bite creates a hole through which blood is then sucked up. This process may initially go unnoticed by the victim because of the injected chemicals which are reported to contain toxins, painkil'~.lers and anticoagulants. The localized area of the wound then swells and becomes painful and extremely itchy.
This condition remains with the victim for several days if left untreated.
Topical application with heparin sodium and zinc derivative in the preferred dosage of 160USP units/g and 5 mg/g was initiated to a number of victims suffering from wounds resulted from these bites and which were in different time durations ranging from being bitten immediate to 12 hours or longer. In all cases the pain and itching relief was prompt, swelling in the wound area remarkably disappeared after one application.
Example 2 A four-year-old girl was playing in the sand on a lakefront beach and was stung by a large wasp in the right shoulder area. The swelling of the sting area was immediate and approximated the size of a dime. One topical application with heparin and zinc derivative in the preferred dosage of 160USP units/g and 5 mg/g was administered within minutes of the sting. Further swelling, redness, aching or pain was not evident after a single application.
Example 3 A 67-year-old man was on a golf outing and accidentally closed his left hand over a small member of the wasp family. He was stung in the upper knuckle area of the third finger resulting in swelling, redness and itching. One topical application using the preferred dosage of 160USP units/g and 5 mg/g of heparin sodium and zinc derivative promptly relieved the itching, pain and swelling with no further discomfort.
Example 4 A 43-year-old woman awoke with several large swollen red and itchy welts caused by an unknown bite. One topical application of :heparin-zinc in the preferred dosage of 160USP units/g and S mg/g quickly reduced the swelling with the redness and itching disappearing.
It is to be understood that the embodiments and variations shown and described herein are merely illustrative of the principles of this invention and that various modifications may be implemented by those skilled in the art without departing from the scope and spirit of the invention.
Modulation of Wound Healing by Other Glycosamynoglycans Topical application of HA to animals has been shown to accelerate skin wound healing (reviewed in Chen and Abatengelo, 1999). HA in wound dressings has been shown to be beneficial for the healing of diabetic foot wounds (Vazquez et al., 2003). The high quantity of HA in fetal when compared to adult tissues is believed to be linked to scarless wound healing observed in fetal tissues (reviewed in Chen and Abatengelo, 1999). The precise mechanism whereby HA assists in wound healing remains to be determined.
While there exist prior art which teaches treatment of insect bites, stings and the like by applying either zinc and/or zinc derivatives or glycosaminoglycans such as heparin alone, there has no reported discovery of combining the medicinal synergies of these two compounds to treat insect bites.
' CA 02465386 2004-04-19 Combination of Zinc Derivatives and Glycosaminoglycayrs Based on the above understanding, the combination of heparin (or other equivalent glycosaminoglycans) and zinc derivatives in a topical application should, in theory, enhance wound repair. The inventor of the present invention discovered and proved that this is, in fact, the case. Both heparin and zinc derivatives enhance epithilialization by different proposed mechanisms and, when mixed, interact in an additive or synergistic fashion to enhance wound repair. Therefore, combined use of a glycosaminoglycan, such as heparin, with a zinc derivative has significant advantages with respect to wound healing after an injury such as insect bites, stings and the like, when compared to the use of either component alone. In addition, zinc derivatives, such as zinc oxide, reduce itching. Unlike other current treatments for treatment of insect bites, stings and the like which are primarily aimed towards minimizing/controlling the allergic/inflammatory reaction and symptomatic relief of pruritus, the present invention is directed towards accelerating wound healing along with a reduction of pruritus. Thus, the use of both a glycosaminoglycan such as heparin with a zinc derivative such as zinc oxide is essential in order to effectively treat insect bites, stings and the like.
Formulation of Heparin and Zinc deYivatives According to the present invention, it has been found that applying zinc derivatives topically in the range of 1-20 mg/g of the gel and heparin derivatives (such as sodium heparin) topically in the range of 100-300 USP units/g of the gel provides effective therapeutic amount for treating insect bites, stings and the like on humans.
Preferably, the optimal dosage used in the treatment is 5 mg/g of zinc derivatives and 160 USP units/g of heparin of the gel.
Based on currently available toxicological data (SCCNFP report on Zinc Oxide, 2003), the stated dosage range for zinc derivatives is safe and well tolerated.
Likewise, the identified dosage range of heparin will not result in significant elevations in plasma heparin levels, hence will not lead to increased bleeding times, and hence will be safe and well-tolerated by the users. These two active ingredients will be applied topically to the skin at the site of the insect bite, sting or the like, in a gel formulation. Suitably, pharmaceutically acceptable carriers may be added to the application gel. Examples of non-medicinal carriers can be selected from the group consisting of carboxymethylcellulose, glycerin, methylparaban, polysorbate, propylparaben and water.
The preferred embodiment of the present invention will be further described by the following examples.
Example 1 The female black fly bite creates a hole through which blood is then sucked up. This process may initially go unnoticed by the victim because of the injected chemicals which are reported to contain toxins, painkil'~.lers and anticoagulants. The localized area of the wound then swells and becomes painful and extremely itchy.
This condition remains with the victim for several days if left untreated.
Topical application with heparin sodium and zinc derivative in the preferred dosage of 160USP units/g and 5 mg/g was initiated to a number of victims suffering from wounds resulted from these bites and which were in different time durations ranging from being bitten immediate to 12 hours or longer. In all cases the pain and itching relief was prompt, swelling in the wound area remarkably disappeared after one application.
Example 2 A four-year-old girl was playing in the sand on a lakefront beach and was stung by a large wasp in the right shoulder area. The swelling of the sting area was immediate and approximated the size of a dime. One topical application with heparin and zinc derivative in the preferred dosage of 160USP units/g and 5 mg/g was administered within minutes of the sting. Further swelling, redness, aching or pain was not evident after a single application.
Example 3 A 67-year-old man was on a golf outing and accidentally closed his left hand over a small member of the wasp family. He was stung in the upper knuckle area of the third finger resulting in swelling, redness and itching. One topical application using the preferred dosage of 160USP units/g and 5 mg/g of heparin sodium and zinc derivative promptly relieved the itching, pain and swelling with no further discomfort.
Example 4 A 43-year-old woman awoke with several large swollen red and itchy welts caused by an unknown bite. One topical application of :heparin-zinc in the preferred dosage of 160USP units/g and S mg/g quickly reduced the swelling with the redness and itching disappearing.
It is to be understood that the embodiments and variations shown and described herein are merely illustrative of the principles of this invention and that various modifications may be implemented by those skilled in the art without departing from the scope and spirit of the invention.
Claims (4)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A composition for treating insect bites and stings, comprising a therapeutically effective amount of zinc oxide and sodium heparin admixed with pharmaceutically acceptable carriers selected from the group consisting of carboxymethylcellulose, glycerin, polysorbate and water, wherein said effective amount for zinc oxide is in the range of 1-20 mg/g and for sodium heparin is in the range of 100-300 USP
units/g of said composition.
units/g of said composition.
2. The composition according to claim 1, wherein said effective amount for zinc oxide is 5 mg/g and for sodium heparin is 160 USP units/g of said composition.
3. Use of zinc oxide and sodium heparin admixed with pharmaceutically acceptable carriers selected from the group consisting of carboxymethylcellulose, glycerin, polysorbate and water, for treating insect bites and stings on human by applying topically to the affected area an effective amount of said zinc oxide and sodium heparin admixture, wherein said effective amount for zinc oxide is in the range of 1-20 mg/g and for sodium heparin is in the range of 100-300 USP units/g of said admixture.
4. The use according to claim 3, wherein said effective amount for zinc oxide is 5 mg/g and for sodium heparin is 160 USP units/g of said admixture.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002465386A CA2465386C (en) | 2004-04-19 | 2004-04-19 | Use of glycosaminoglycans and zinc derivatives for insect bites, stings and the like |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002465386A CA2465386C (en) | 2004-04-19 | 2004-04-19 | Use of glycosaminoglycans and zinc derivatives for insect bites, stings and the like |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2465386A1 CA2465386A1 (en) | 2005-10-19 |
CA2465386C true CA2465386C (en) | 2009-05-26 |
Family
ID=35276879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002465386A Expired - Lifetime CA2465386C (en) | 2004-04-19 | 2004-04-19 | Use of glycosaminoglycans and zinc derivatives for insect bites, stings and the like |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2465386C (en) |
-
2004
- 2004-04-19 CA CA002465386A patent/CA2465386C/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2465386A1 (en) | 2005-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7902171B2 (en) | Composition for treating inflammatory diseases | |
US5731298A (en) | Method for the treatment of scars and keloids | |
US5529987A (en) | Hyaluronic acid-urea pharmaceutical compositions and uses | |
JPH04500797A (en) | Uses of sucralfate | |
WO2008037262A1 (en) | Wound healing composition comprising phosphate, iron and copper | |
CA2247198C (en) | Topical pharmaceutical composition containing heparin | |
US20180116986A1 (en) | Composition of novel powder formulations of tranexamic acid | |
US20140363486A1 (en) | Methods for reducing or altering scar formation | |
JP2001510152A (en) | Anti-hyperalgesic anesthetic drug film-forming composition, and method for treating hyperalgesia and pruritus associated therewith | |
WO2003041723A1 (en) | Pharmaceutical applications of hyaluronic acid preparations | |
CN104906029A (en) | Nasal cavity preparation and preparing method and application thereof | |
CA2465386C (en) | Use of glycosaminoglycans and zinc derivatives for insect bites, stings and the like | |
US20050233005A1 (en) | Use of glycosaminoglycans and zinc derivatives for insect bites, stings and the like | |
JP2003528147A (en) | Pharmaceutical gel composition | |
CN110251613A (en) | A kind of compound preparation and preparation method thereof for treating hand decortication | |
TW201940178A (en) | Topical dermatological composition | |
KR101607229B1 (en) | A composition for treating wound containing horse oil | |
RU2784202C1 (en) | Ointment mesh atraumatic bandage | |
JP7441943B2 (en) | Topical antibiotics including pharmaceutical compositions for bacterial infections and wound healing | |
RU2369387C2 (en) | Pharmaceutical composition for local and external application when treating traumatic and post-operation injuries of peripheral nervous system | |
RU2722127C1 (en) | Wound healing product in the form of an ointment containing rubidium chloride | |
RU2682454C1 (en) | Ointment for treatment of thermal burns and method for treatment thereof | |
Post-Operative | IN-DEPTH REVIEW | |
DE10209966A1 (en) | Pharmaceutical applications of hyaluronic acid preparations | |
US20070265346A1 (en) | Combination therapy for the treatment and improvement of scars |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20240419 |